转移性结直肠癌患者呋喹替尼治疗相关心血管毒性发生率和风险的Meta分析

doi:10.12114/j.issn.1007-9572.2024.0203

中国全科医学 ›› 2025, Vol. 28 ›› Issue (23): 2934-2940.DOI: 10.12114/j.issn.1007-9572.2024.0203

所属专题：心血管最新文章合辑

• 医学循证 • 上一篇

转移性结直肠癌患者呋喹替尼治疗相关心血管毒性发生率和风险的Meta分析

王笑林¹, 李秋月¹, 周彦君², 张金辉³, 梁涛¹^,^*()

1．100144　北京市，中国医学科学院　北京协和医学院护理学院
2．100045　北京市，国家儿童医学中心　首都医科大学附属北京儿童医院护理部
3．100021　北京市，中国医学科学院　北京协和医学院肿瘤医院内科

收稿日期:2024-04-19 修回日期:2024-08-06 出版日期:2025-08-15 发布日期:2025-06-17
通讯作者: 梁涛
作者贡献：
所有作者为本研究的构思和设计作出贡献；王笑林进行文献检索、筛选、稿件撰写；李秋月和周彦君进行数据提取和分析；张金辉和梁涛负责稿件审校。

Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis

WANG Xiaolin¹, LI Qiuyue¹, ZHOU Yanjun², ZHANG Jinhui³, LIANG Tao¹^,^*()

1. School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100144, China
2. Department of Nursing, Beijing Children's Hospital, Capital Medical University/National Center for Children's Health, China, Beijing 100045, China
3. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China

Received:2024-04-19 Revised:2024-08-06 Published:2025-08-15 Online:2025-06-17
Contact: LIANG Tao

分享到

摘要/Abstract

摘要： 背景 38.4%的结直肠癌患者死于非癌症疾病，其中心血管疾病是最主要原因，占总死亡人数的20.3%。靶向治疗相关的心血管毒性并不少见，最突出的为高血压。目的本研究旨在探讨转移性结直肠癌患者呋喹替尼治疗相关心血管毒性的发生率和风险。方法系统检索中国知网、万方数据知识服务平台、中国生物医学文献数据库、Web of Science、PubMed、Cochrane Library、Embase数据库中有关转移性结直肠癌患者呋喹替尼治疗的单臂临床试验和随机对照试验，检索时限为建库至2024年5月。由2名研究者独立进行文献筛选、资料提取及质量评价，使用R 4.3.3软件进行Meta分析。结果共纳入8篇文献，涉及6项单臂临床试验、3项随机对照试验。Meta分析结果显示：全级别高血压和出血的发生率为35%（95%CI=0.25~0.45）和24%（95%CI=0.10~0.37）。在高级别事件中，高血压发生率为15%（95%CI=0.10~0.20），出血发生率为1%（95%CI=0~0.02），血栓栓塞发生率为3%（95%CI=0.02~0.05），心脏疾病发生率为1%（95%CI=0~0.02）。呋喹替尼与全级别、高级别高血压及全级别出血的风险增加相关，RR分别为3.93（95%CI=2.95~5.24）、12.33（95%CI=5.31~28.63）及1.84（95%CI=1.36~2.50），但与高级别的出血（RR=1.06，95%CI=0.35~3.23）、血栓栓塞事件（RR=3.35，95%CI=0.89~12.55）及心脏疾病（RR=0.62，95%CI=0.18~2.14）无关。结论呋喹替尼与转移性结直肠癌患者心血管毒性发生率和风险增加显著相关，但主要针对的是低级别事件。

关键词: 转移性结直肠癌, 呋喹替尼, 心血管毒性, Meta分析

Abstract:

Background

38.4% of patients with colorectal cancer died from non-cancer disease, with cardiovascular disease being the most important cause, accounting for 20.3% of the total deaths. Cardiovascular toxicity associated with targeted therapy is not uncommon, most notably hypertension.

Objective

The study aimed to determine the overall incidence and risk of cardiovascular toxicity associated with fruquintinib in metastatic colorectal cancer.

Methods

We searched CNKI, Wanfang Data, CBM, PubMed, Embase, Web of Science and Cochrane Library databases for single-arm clinical trials and randomized controlled trials (RCTs) relevant to fuquintinib therapy in patients with metastatic colorectal cancer. The search time limit was from the establishment of the databases to May 2024. Literature screening, data extraction, and quality evaluation were performed independently by two investigators. The meta-analysis was conducted using R 4.3.3 software.

Results

Eight articles involving six single-arm clinical trials and three randomized controlled trials were included. The meta-analysis results showed that the incidence rates of all-grade hypertension and hemorrhage were 35% (95%CI=0.25-0.45) and 24% (95%CI=0.10-0.37), respectively. For high-grade events, the rates were 15% for hypertension (95%CI=0.10-0.20), 1% for hemorrhage (95%CI=0-0.02), 3% for embolic and thrombotic events (95%CI=0.02-0.05), and 1% for cardiac diseases (95%CI=0-0.02). Fruquintinib was associated with increased risks for both all-grade and high-grade hypertension, as well as all-grade hemorrhage, with RR of 3.93 (95%CI=2.95-5.24), 12.33 (95%CI=5.31-28.63), and 1.84 (95%CI=1.36-2.50) respectively, but not for high-grade hemorrhage (RR=1.06, 95%CI=0.35-3.23), embolic and thrombotic events (RR=3.35, 95%CI=0.89-12.55), or cardiac diseases (RR=0.62, 95%CI=0.18-2.14) .

Conclusion

The use of fruquintinib is associated with a significantly increased risk of developing cardiovascular toxicity, primarily for lower-grade events, in patients with metastatic colorectal cancer.

Key words: Metastatic colorectal cancer, Fruquintinib, Cardiovascular toxicity, Meta-analysis

中图分类号:

R 735.34

王笑林,李秋月,周彦君,等. 转移性结直肠癌患者呋喹替尼治疗相关心血管毒性发生率和风险的Meta分析[J]. 中国全科医学, 2025, 28(23): 2934-2940. DOI: 10.12114/j.issn.1007-9572.2024.0203.
WANG Xiaolin,LI Qiuyue,ZHOU Yanjun, et al. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis[J]. Chinese General Practice, 2025, 28(23): 2934-2940. DOI: 10.12114/j.issn.1007-9572.2024.0203.

图/表 15

图1 文献筛选流程图

Figure 1 Literature screening flowchart

表1 纳入研究的基本特征

Table 1 Characteristics of the included studies

第一作者	发表时间（年）	试验阶段	治疗方案	暴露时间[M（P₂₅，P₇₅）或M（Min，Max），月]	样本量（例）	随访时间（月）	中位年龄[M（P₂₅，P₇₅）或M（Min，Max），岁]	NCI-CTCAE版本	MINORS分数（分）	结局指标
LI^[2]	2018	Ⅲ期	呋喹替尼+BSC	3.7（0.1~21.9）	278	13.3	55（23~75）	5.0		①②③④
			安慰剂+BSC	1.8（0.1~11.1）	137	13.2	57（24~74）
DASARI^[4]	2023	Ⅲ期	呋喹替尼+BSC	3.1（1.8~5.6）	456	11.3	64（56~70）	5.0		①②③ ④⑤⑥
			安慰剂+BSC	1.8（1.0~2.3）	230	11.2	64（56~69）
XU^[9]	2017	Ⅱ期	呋喹替尼+BSC	3.2	47	NR	50（25~69）	4.03		①②⑤⑥
			安慰剂+BSC	0.8	24	NR	54（38~70）
TAN^[10]	2023	Ⅱ期	呋喹替尼	NR	29	NR	69（65~77）	4.0	14	①②③④
ZHAO^[11]	2023	Ⅱ期	呋喹替尼+PD-1	7.5（3~18）	20	13.7	52（30~71）	5.0	14	①②
MA^[12]	2023	Ⅱ期	呋喹替尼+PD-1+粪便移植	NR	19	NR	62（42~79）	5.0	12	①②
GUO^[13]	2023	Ⅱ期	呋喹替尼+PD-1	NR	44	NR	50（25~69）	4.03	13	①②
XU^[9]	2017	Ⅰb期	呋喹替尼	NR	42	NR	55.5（33~70）	4.03	13	①②⑤⑥
LI^[3]	2024	Ⅳ期	呋喹替尼或呋喹替尼+PD-1或呋喹替尼+化疗	2.7（1.4~5.7）	2798	NR	60（52~67）	4.03	12	①②

表2 随机对照试验的质量评价

Table 2 Quality assessment of the randomized controlled trials

第一作者	随机化过程中产生的偏倚	偏离预期干预措施而导致的偏倚	由于结果数据缺失引起的偏倚	结果测量偏倚	报告结果选择偏倚	总体偏倚
LI^[2]	存在一定风险	低	低	低	低	低
DASARI^[4]	存在一定风险	低	低	低	低	低
XU^[9]	存在一定风险	低	低	低	低	低

图2 呋喹替尼治疗转移性结直肠癌患者全级别高血压发生率的森林图

Figure 2 Forest plot of all-grade hypertension incidence for fuquintinib therapy in patients with metastatic colorectal cancer

图3 试验组和对照组全级别高血压发生风险比较的森林图

Figure 3 Forest plot for comparing RR of all-grade hypertension between trial group and control group

图4 呋喹替尼治疗转移性结直肠癌患者高级别高血压发生率的森林图

Figure 4 Forest plot of high-grade hypertension incidence for fuquintinib therapy in patients with metastatic colorectal cancer

图5 试验组和对照组高级别高血压发生风险比较的森林图

Figure 5 Forest plot for comparing RR of high-grade hypertension between trial group and control group

图6 呋喹替尼治疗转移性结直肠癌患者全级别出血发生率的森林图

Figure 6 Forest plot of all-grade hemorrhage incidence for fuquintinib therapy in patients with metastatic colorectal cancer

图7 试验组和对照组全级别出血发生风险比较的森林图

Figure 7 Forest plot for comparing RR of all-grade hemorrhage between trial group and control group

图8 呋喹替尼治疗转移性结直肠癌患者高级别出血发生率的森林图

Figure 8 Forest plot of high-grade hemorrhage incidence for fuquintinib therapy in patients with metastatic colorectal cancer

图9 试验组和对照组高级别出血发生风险比较的森林图

Figure 9 Forest plot for comparing RR of high-grade hemorrhage between trial group and control group

图10 呋喹替尼治疗转移性结直肠癌患者高级别血栓栓塞发生率的森林图

Figure 10 Forest plot of high-grade embolic and thrombotic events incidence for fuquintinib therapy in patients with metastatic colorectal cancer

图11 试验组和对照组高级别血栓栓塞发生风险比较的森林图

Figure 11 Forest plot for comparing RR of high-grade embolic and thrombotic events between trial group and control group

图12 呋喹替尼治疗转移性结直肠癌患者高级别心脏疾病发生率的森林图

Figure 12 Forest plot of high-grade cardiac disease incidence for fuquintinib therapy in patients with metastatic colorectal cancer

图13 试验组和对照组高级别心脏疾病发生风险比较的森林图

Figure 13 Forest plot for comparing RR of high-grade cardiac disease between trial group and control group

参考文献 27

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249. DOI：10.3322/caac.21660.
[2]	LI J, QIN S K, XU R H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer：the FRESCO randomized clinical trial[J]. JAMA，2018，319(24)：2486-2496. DOI：10.1001/jama.2018.7855.
[3]	LI J, WANG Z Q, ZHONG H J, et al. A phase Ⅳ study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice[J]. Oncologist，2024，29(8)：e1012-1019. DOI：10.1093/oncolo/oyae073.
[4]	DASARI A, LONARDI S, GARCIA-CARBONERO R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer（FRESCO-2）：an international，multicentre，randomised，double-blind，phase 3 study[J]. Lancet，2023，402(10395)：41-53. DOI：10.1016/S0140-6736(23)00772-9.
[5]	LI J, GU J. Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients：a meta-analysis of 77 randomized controlled trials[J]. Clin Drug Investig，2018，38(12)：1109-1123. DOI：10.1007/s40261-018-0709-2.
[6]	TOTZECK M, MINCU R I, MROTZEK S, et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity：a meta-analysis of approximately 29，000 cancer patients[J]. Eur J Prev Cardiol，2018，25(5)：482-494. DOI：10.1177/2047487318755193.
[7]	GALVANO A, GUARINI A, IACONO F, et al. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy[J]. Expert Opin Drug Saf，2019，18(6)：485-496. DOI：10.1080/14740338.2019.1613371.
[8]	HUEDO-MEDINA T B, SÁNCHEZ-MECA J, MARÍN-MARTÍNEZ F, et al. Assessing heterogeneity in meta-analysis：Q statistic or I² index?[J]. Psychol Methods，2006，11(2)：193-206. DOI：10.1037/1082-989X.11.2.193.
[9]	XU R H, LI J, BAI Y X, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer：a phase Ib study and a randomized double-blind phase Ⅱ study[J]. J Hematol Oncol，2017，10(1)：22. DOI：10.1186/s13045-016-0384-9.
[10]	TAN S R, ZHANG S Y, ZHOU N, et al. Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer：a single-arm，multicenter，phase Ⅱ study[J]. Cancer Med，2023，12(24)：22038-22046. DOI：10.1002/cam4.6786.
[11]	ZHAO W, LEI J, KE S, et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer：an open-label，single-arm，phase Ⅱ trial（RENMIN-215）[J]. EClinicalMedicine，2023，66：102315. DOI：10.1016/j.eclinm.2023.102315.
[12]	MA S C, CHEN R, DUAN L, et al. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer：results of a single-arm，single-center，prospective，phaseⅡ clinical study[J]. J Gastrointest Oncol，2023，14(2)：1052-1063. DOI：10.21037/jgo-23-108.
[13]	GUO Y, ZHANG W J, YING J E, et al. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours：the dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases[J]. Eur J Cancer，2023，181：26-37. DOI：10.1016/j.ejca.2022.12.004.
[14]	WANG Z X, XU J, NIE W W, et al. Risk of hypertension with regorafenib in cancer patients：a systematic review and meta-analysis[J]. Eur J Clin Pharmacol，2014，70(2)：225-231. DOI：10.1007/s00228-013-1598-1.
[15]	TOUYZ R M, HERRMANN S M S, HERRMANN J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events[J]. J Am Soc Hypertens，2018，12(6)：409-425. DOI：10.1016/j.jash.2018.03.008.
[16]	LIU B, DING F X, LIU Y, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients：a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients[J]. Oncotarget，2016，7(41)：67661-67673. DOI：10.18632/oncotarget.11813.
[17]	HOU W T, DING M F, LI X H, et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors：a Bayesian network analysis of randomized controlled trials[J]. J Cancer Res Clin Oncol，2021，147(8)：2407-2420. DOI：10.1007/s00432-021-03521-w.
[18]	QI W X, TANG L N, SUN Y J, et al. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors：an up-to-date meta-analysis of 27 randomized controlled trials[J]. Ann Oncol，2013，24(12)：2943-2952. DOI：10.1093/annonc/mdt292.
[19]	LIU B, DING F X, ZHANG D Y, et al. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs：a meta-analysis[J]. Cancer Chemother Pharmacol，2017，80(3)：487-495. DOI：10.1007/s00280-017-3386-6.
[20]	WU Y Y, FAN Y W, DONG D F, et al. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer：an adjusted indirect meta-analysis and systematic review[J]. Ther Adv Med Oncol，2020，12：1758835920940932. DOI：10.1177/1758835920940932.
[21]	ZHU J, ZHOU R, ZHANG B L. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer：a systematic review and network meta-analysis[J]. J Cancer Res Clin Oncol，2019，145(9)：2313-2323. DOI：10.1007/s00432-019-02964-6.
[22]	MERCIER J, VOUTSADAKIS I A. A systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer[J]. Anticancer Res，2017，37(11)：5925-5934. DOI：10.21873/anticanres.12039.
[23]	CHEN J Y, ZHENG Y Q, WANG H H, et al. Cause of death among patients with colorectal cancer：a population-based study in the United States[J]. Aging，2020，12(22)：22927-22948. DOI：10.18632/aging.104022.
[24]	STURGEON K M, DENG L, BLUETHMANN S M, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients[J]. Eur Heart J，2019，40(48)：3889-3897. DOI：10.1093/eurheartj/ehz766.
[25]	SUNDARARAJAN S, KUMAR A, POONGKUNRAN M, et al. Cardiovascular adverse effects of targeted antiangiogenic drugs：mechanisms and management[J]. Future Oncol，2016，12(8)：1067-1080. DOI：10.2217/fon.16.4.
[26]	ZHANG X, GAO Y Q, YANG B Y, et al. The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity[J]. Int Immunopharmacol，2023，117：109895. DOI：10.1016/j.intimp.2023.109895.
[27]	PANTAZI D, TSELEPIS A D. Cardiovascular toxic effects of antitumor agents：Pathogenetic mechanisms[J]. Thromb Res，2022，213(Suppl 1)：S95-102. DOI：10.1016/j.thromres.2021.12.017.

转移性结直肠癌患者呋喹替尼治疗相关心血管毒性发生率和风险的Meta分析

Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 15

参考文献 27

相关文章 15

编辑推荐

Metrics

留言

[1]	李浩, 李江涛, 刘丹, 王建军. 贝利尤单抗和阿尼鲁单抗及泰它西普治疗系统性红斑狼疮疗效和安全性的网状Meta分析[J]. 中国全科医学, 2025, 28(23): 2924-2933.
[2]	马盼盼, 王思静, 游娜, 丁大法, 鲁一兵. Danuglipron与Orforglipron治疗2型糖尿病疗效及安全性的Meta分析[J]. 中国全科医学, 2025, 28(21): 2679-2685.
[3]	胡婉琴, 余深艳, 曹学华, 向凤, 贾钰. 中国儿童性早熟影响因素的Meta分析[J]. 中国全科医学, 2025, 28(21): 2661-2671.
[4]	阿迪力·吐尔孙, 程刚. 非奈利酮治疗2型糖尿病肾病有效性和安全性的Meta分析[J]. 中国全科医学, 2025, 28(21): 2686-2691.
[5]	郭盛滕, 张芬芬, 万迪, 于冬梅, 王庆华. 重症急性胰腺炎并发急性肺损伤危险因素的Meta分析[J]. 中国全科医学, 2025, 28(20): 2546-2554.
[6]	王碧晴, 张萍, 杨红霞, 王倩, 鞠春晓, 赵俊男, 梅俊, 张颖, 徐凤芹. 中国老年高血压患者轻度认知障碍患病率及发展趋势的Meta分析[J]. 中国全科医学, 2025, 28(17): 2186-2192.
[7]	樊宇, 李蓉, 龚双英, 杨小娟, 李蕊. 中国产妇配偶产后抑郁发生率的Meta分析[J]. 中国全科医学, 2025, 28(17): 2179-2185.
[8]	何芸, 范焕芳, 马盼, 许绍青, 杨柳, 金明哲, 张明蕊, 陈佳琪. 不同针灸治疗方式干预乳腺癌术后上肢淋巴水肿效果的网状Meta分析[J]. 中国全科医学, 2025, 28(14): 1788-1794.
[9]	朱胜杰, 刁华琼, 杭晓屹, 孙文军. 不同中成药注射液治疗后循环缺血性眩晕效果的网状Meta分析[J]. 中国全科医学, 2025, 28(14): 1795-1808.
[10]	王晓雨, 冯贞贞, 王军, 郭小川, 李建生. 急性呼吸窘迫综合征患者并发急性肾损伤危险因素的系统评价[J]. 中国全科医学, 2025, 28(12): 1527-1537.
[11]	迟洵, 刘思思, 陈巧, 胡玥, 王伟仙. 不同营养筛查工具对肝硬化患者营养筛查适用性的网状Meta分析[J]. 中国全科医学, 2025, 28(11): 1395-1402.
[12]	史健, 王亚静, 侯冉, 黄娅婕, 段晓阳. 表皮生长因子受体酪氨酸激酶抑制剂联合化疗一线治疗表皮生长因子受体突变晚期非小细胞肺癌疗效及安全性的Meta分析[J]. 中国全科医学, 2025, 28(11): 1383-1394.
[13]	谷明宇, 秦廷廷, 乔昆, 白欣苑, 王尧, 杨宇彤, 李星明. 中国基层高血压管理模式的网状Meta分析[J]. 中国全科医学, 2025, 28(10): 1265-1272.
[14]	杨水华, 姚桂英, 田晨, 晏毅龙, 刘嘉艺, 王佳佳, 田金徽, 牛猛, 葛龙. MetaDTA：一款诊断试验准确性Meta分析在线应用程序[J]. 中国全科医学, 2025, 28(08): 1023-1032.
[15]	刘芹, 程敏, 江凤琼, 李小玉. 中国儿童青少年遗尿症患病率及影响因素的Meta分析[J]. 中国全科医学, 2025, 28(06): 763-770.